Catalog No.
Product Name
Application
Product Information
Citations
-
EGFR Inhibitor
EGFR-IN-136 is a potent inhibitor of the epidermal growth factor receptor (EGFR), demonstrating IC50 values of 20.2 nM for EGFRWT, 1.2 nM for EGFRLR/TM, 2.3 nM for EGFR19D/TM/CS, and 12.5 nM for EGFRLR/TM/CS. This compound exhibits significant antiproliferative and antitumor activity, making it a valuable tool for research involving non-small cell lung cancer (NSCLC). Its selective inhibition of various EGFR mutations positions EGFR-IN-136 as an important reagent for investigating therapeutic strategies targeting EGFR-related pathways. -
EGFR Inhibitor
EGFR-IN-145 is a selective inhibitor of the epidermal growth factor receptor (EGFR) kinase. At a concentration of 20 μM, it demonstrates a 52.7% inhibition of EGFR-wild type kinase activity. This compound is valuable for research in cancer biology, particularly in the study of oncogenic signaling pathways and the development of targeted therapies for EGFR-driven tumors. -
EGFR Substrate
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is a phosphorylated peptide that serves as a substrate for the epidermal growth factor receptor (EGFR). This product is utilized for the evaluation of EGFR kinase inhibitors through the quantification of phosphorylated substrates, aiding in the exploration of signaling pathways and potential therapeutic applications in cancer research. Its precise autophosphorylation site makes it an essential tool for discerning kinase activity in various biological assays. -
EGFR-TK Inhibitor
NSC81111 is a potent orally active inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFR-TK), demonstrating an IC50 of 0.15 nM. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Its efficacy in targeting EGFR pathways positions NSC81111 as a promising candidate for studies focused on cancer therapeutics and mechanisms of resistance. -
EGFR Inhibitor
Paeciloquinone D is an inhibitor of the epidermal growth factor receptor (EGFR) protein tyrosine kinase. It exhibits significant biological activity by blocking EGFR signaling pathways, which are critical in tumor growth and proliferation. This compound is relevant for research applications focused on cancer biology and targeted therapies for EGFR-driven malignancies. -
EGFR Tyrosine Kinase Inhibitor
BML-265 is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It disrupts Golgi integrity and inhibits the secretory transport of various protein cargos in human cells, but shows no effect in rodent cells. This specificity makes BML-265 a valuable tool for studying EGFR signaling pathways and Golgi function in human cellular contexts. -
EGFR Inhibitor
Tyrphostin 63 is a selective inhibitor of the epidermal growth factor receptor (EGFR). Exhibiting an IC50 value of 375 μM and a Ki value of 123 μM, Tyrphostin 63 effectively modulates EGFR signaling pathways. This compound is primarily utilized in cancer research to investigate the role of EGFR in tumor proliferation and metastasis. -
EGFR Inhibitor
EGFR-IN-149 is a selective inhibitor of the epidermal growth factor receptor (EGFR), exhibiting an IC50 of 0.42 nM. This compound effectively blocks EGFR signaling, which is crucial in regulating cellular proliferation and survival. Its prominent biological activity makes it a valuable tool for research applications focused on cancer therapies, particularly in studies involving EGFR-dependent tumor growth and resistance mechanisms. -
EGFR Inhibitor
EGFR-IN-146 is an inhibitor of the epidermal growth factor receptor (EGFR) that disrupts EGFR signaling, effectively enhancing insulin sensitivity through AMPK pathway activation. This compound exhibits significant potential in reducing blood glucose levels and body weight. EGFR-IN-146 is valuable for research applications focused on diabetes and obesity, offering insights into metabolic regulation and potential therapeutic options. -
EGFR Inhibitor
DDC4002 is a selective inhibitor of the epidermal growth factor receptor (EGFR), targeting the L858R/T790M mutant subtype with an IC50 of 39 nM. This compound exhibits potent inhibitory activity, making it a valuable tool for cancer research, particularly in studies focused on therapeutic resistance in non-small cell lung cancer. Its application supports investigations into the mechanisms of EGFR-driven malignancies and offers insights into potential treatment strategies. -
EGFR Inhibitor
Paeciloquinone E is a selective inhibitor of the epidermal growth factor receptor (EGFR) protein tyrosine kinase. This compound demonstrates significant biological activity in modulating cell proliferation and survival pathways associated with EGFR signaling. It serves as a valuable tool in cancer research, particularly for studying the effects of EGFR inhibition in various tumor models. -
EGFR Ligand
EGFR ligand-11 is a specific ligand for the epidermal growth factor receptor (EGFR). This compound plays a crucial role in synthesizing PROTAC MS154, facilitating targeted protein degradation of EGFR-related pathways. It is valuable for research applications focused on understanding EGFR signaling and developing therapeutic strategies for EGFR-driven cancers. -
EGFR Inhibitor
NRC-2694-A is a potent orally bioavailable inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It exhibits significant activity against malignant squamous cell carcinoma (HNSCC), making it a valuable tool for researchers investigating EGFR-related signaling pathways and therapeutic strategies in cancer treatment. Its application in preclinical studies may enhance understanding of tumorigenesis and resistance mechanisms associated with EGFR inhibition. -
EGFR Inhibitor
PF-6422899 is a selective inhibitor of the epidermal growth factor receptor (EGFR) that exhibits binding affinity in the nanomolar range. It demonstrates potent biological activity against EGFR, making it a valuable tool in cancer research, particularly in studies focused on EGFR-driven pathways. Additionally, PF-6422899 may also interact with SOAT1, suggesting potential applications in the modulation of lipid metabolism in cancer cells. -
EGFR/ERBB2 Inhibitor
HKI-357 dimaleate is an irreversible dual inhibitor targeting EGFR and ERBB2, exhibiting IC50 values of 34 nM and 33 nM, respectively. This compound effectively suppresses EGFR autophosphorylation at tyrosine 1068, as well as the phosphorylation of downstream signaling molecules AKT and MAPK. HKI-357 dimaleate is primarily used in research to investigate mechanisms of oncogenesis and assess potential therapeutic strategies in cancer that involve EGFR and ERBB2 pathways. -
EGFR Inhibitor
Paeciloquinone F is a potent inhibitor of the epidermal growth factor receptor (EGFR) protein tyrosine kinase. It has been demonstrated to effectively impede EGFR signaling pathways, making it a valuable tool for studies focused on cancer research and therapeutic development. The compound's ability to modulate EGFR activity facilitates investigations into tumor growth and progression, as well as the potential for targeted cancer therapies. -
EGFR Inhibitor
Paeciloquinone C is a potent inhibitor of the epidermal growth factor receptor (EGFR) protein tyrosine kinase. It effectively inhibits the V-abl protein tyrosine kinase with an IC50 value of 0.56 μM. This compound is utilized in research focused on cancer biology and targeted therapies, providing insights into the mechanisms of EGFR-mediated signal transduction. -
EGFR Inhibitor
1,2,3,4-Tetrahydro Staurosporin is a selective inhibitor of the mutant epidermal growth factor receptor (EGFR), particularly EGFRT790M, with an IC50 of 74 nM, demonstrating potential in targeting drug-resistant mutations. This compound also exhibits a higher IC50 of 390 nM against wild-type EGFR, highlighting its specificity. Additionally, 1,2,3,4-Tetrahydro Staurosporin interacts with Janus kinase 3 (JAK3), making it suitable for research applications focused on cancer biology and signaling pathways. -
EGFR/HER2 Mutant Inhibitor
EGFR-IN-99 is a potent inhibitor specifically targeting EGFR and HER2 Exon 20 insertion mutants. This compound exhibits exceptional antiproliferative activity in DFCI127 cells, with an EC50 value of 11.5 nM. EGFR-IN-99 is designed for research applications related to non-small cell lung cancer (NSCLC), making it a valuable tool for studying mutant-driven tumorigenesis and therapeutic resistance. -
EGFR Inhibitor
Paeciloquinone A is a selective inhibitor of the epidermal growth factor receptor (EGFR) protein tyrosine kinase. This compound demonstrates significant biological activity by inhibiting V-abl protein tyrosine kinase with an IC50 value of 0.59 μM. It is utilized in research for investigating EGFR-related signaling pathways and potential therapeutic applications in cancer treatment. -
EGFR Inhibitor
Paeciloquinone B is an inhibitor of the EGFR (epidermal growth factor receptor) protein tyrosine kinase. This compound demonstrates significant biological activity in obstructing EGFR signaling pathways, making it a valuable tool in cancer research, particularly for the study of tumor growth and proliferation. Its application in the investigation of specific cancer types associated with EGFR overexpression provides insights into potential therapeutic strategies. -
EGFR Inhibitor
LDC0496 is a potent and selective inhibitor of the epidermal growth factor receptor (EGFR). It demonstrates strong inhibitory activity against both EGFR and Her2 exon 20 insertion mutations, while maintaining selectivity for wild-type EGFR and demonstrating minimal cross-reactivity within the kinome. This compound is valuable for research applications focused on targeted therapies in cancers associated with EGFR mutations. -
EGFR Inhibitor
EGFR-IN-9 is a potent inhibitor of the epidermal growth factor receptor (EGFR) kinase, exhibiting IC50 values of 7 nM for wild-type EGFR and 28 nM for the double mutant EGFR (L858R/T790M). This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research, particularly in studies focusing on EGFR-related pathways and mutations. It is suitable for investigations into therapeutic strategies targeting EGFR in various cancer models. -
EGFR L858R/T790M Inhibitor
Antiproliferative agent-34 is a selective inhibitor targeting EGFR L858R/T790M with an IC50 of 177 nM, while exhibiting inhibition of EGFR WT at 1567 nM. This compound also effectively inhibits several kinases, including JAK2, ROS1, FLT3, FLT4, and PDGFRα with IC50 values ranging from approximately 30 nM to 226 nM. Antiproliferative agent-34 demonstrates significant anti-proliferative activity in H1975 and HCC827 cancer cell lines, with IC50 values below 40 nM under normoxic conditions, and enhanced potency of 4–6-fold under hypoxic conditions, making it a valuable tool for cancer research focused on targeted therapies. -
EGFR Inhibitor
BPIQ-II hydrochloride is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, exhibiting an IC50 value of 8 pM. This compound selectively targets EGFR while showing minimal interaction with various other tyrosine and serine/threonine kinases. In cellular studies, BPIQ-II effectively penetrates cells and specifically disrupts EGF-stimulated signal transduction by competitively binding to the ATP site of EGFR. This makes it a valuable tool for research into EGFR-related signaling pathways and targeted cancer therapies. -
EGFR inhibitor
EGFR-IN-82 is a highly selective and orally bioavailable inhibitor of the epidermal growth factor receptor (EGFR), exhibiting IC50 values of 0.09 nM for the EGFRL858R/T790M/C797S mutant and 0.06 nM for EGFRDel19/T790M/C797S. This compound demonstrates significant anti-proliferative effects and inhibits tumor formation in nude mice models. EGFR-IN-82 is a valuable tool for research into non-small cell lung cancer, particularly in studies focused on resistant EGFR mutations. -
EGFR/HER2 Inhibitor
EGFR/HER2-IN-19 is a potent dual inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). This compound exhibits significant anti-proliferative activity in cancer cells driven by EGFR and HER2 signaling pathways. It serves as a valuable tool for research applications focused on understanding and targeting EGFR/HER2-mediated tumorigenesis. -
EGFR Inhibitor
Antiproliferative agent-54 is a potent EGFR inhibitor that targets multiple kinases, including ABL WT, B-RAF, HCK, LYN A, and SRC, with IC50 values ranging from 6 to 50 nM. This compound effectively reduces the proliferation of various cancer cell lines and shows significant inhibitory effects on human umbilical vein endothelial cells (HUVEC) and HepG2 cells, with EC50 values of 34 and 38 nM, respectively. Antiproliferative agent-54 also demonstrates favorable pharmacokinetic properties in rat models, supporting its potential for further research applications in cancer therapy. -
EGFR Inhibitor
EGFR-IN-18 is a selective inhibitor of the epidermal growth factor receptor (EGFR), specifically targeting the L858R/T790M/C797S mutant variant with a potency of 4.9 nM. In contrast, it exhibits reduced activity against wild-type EGFR at 47 nM. This compound is valuable for studying EGFR-driven cancer models and may facilitate the development of targeted therapies in oncology research. -
EGFR Inhibitor
Tyrphostin 8 is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, exhibiting an IC50 of 560 μM. Additionally, it acts as a GTPase inhibitor and can effectively inhibit the protein serine/threonine phosphatase calcineurin, with an IC50 of 21 μM. Tyrphostin 8 is utilized in research applications focusing on cancer biology, signal transduction pathways, and the regulation of cellular processes influenced by EGFR signaling. -
EGFR Inhibitor
EGFR-IN-48 is a highly potent and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting IC50 values of 0.193 nM, 0.251 nM, and 10.4 nM against EGFR del19/TM/CS, EGFRLR/TM/CS, and EGFR wild-type, respectively. This compound effectively inhibits the proliferation of BaF3 cells harboring the EGFR del19/T790M/C797S mutation, as well as PC-9 cells with IC50s of 1.526 nM and 66.7 nM, respectively. EGFR-IN-48 is a valuable tool for research focused on cancer therapeutics, particularly in studies regarding EGFR mutation-related resistance mechanisms. -
EGFR Inhibitor
EGFR-IN-198 is a selective inhibitor of the epidermal growth factor receptor (EGFR), exhibiting subnanomolar irreversible inhibition. This compound covalently binds to the kinase domain of EGFR, effectively disrupting its autophosphorylation and downstream signaling pathways. EGFR-IN-198 is utilized in research focusing on cancer biology, particularly in studies investigating EGFR-driven tumors and potential therapeutic interventions targeting this pathway. -
EGFR Inhibitor
EGFR-IN-53 is a potent inhibitor of the epidermal growth factor receptor (EGFR), exhibiting an IC50 of 8.264 µM. This compound demonstrates significant cytotoxic activity against various cancer cell lines, making it a valuable tool for cancer research. EGFR-IN-53 can be employed in studies investigating EGFR-mediated signaling pathways, therapeutic resistance, and potential combination therapies in oncology. -
EGFR Inhibitor
EGFR-IN-90 is a potent orally active inhibitor targeting the epidermal growth factor receptor (EGFR). It demonstrates significant inhibitory activity against the EGFRL858R/T790M/C797S mutations, with an IC50 of 5.1 nM. Additionally, EGFR-IN-90 effectively reduces proliferation in the H1975-TM cell line associated with these mutations, exhibiting an IC50 of 0.05 μM. In vivo, it has been shown to inhibit tumor growth in the H1975-TM xenograft tumor model, making it a valuable tool for cancer research focused on EGFR-related pathways. -
EGFR Ligand
EGFR ligand-14 is a specific ligand for the Epidermal Growth Factor Receptor (EGFR), a key target in cancer research. This compound facilitates studies on EGFR signaling pathways and can be utilized in the synthesis of SJF-1521. Its role in modulating EGFR activity makes it valuable for the investigation of targeted therapies in oncogenic processes. -
EGFR Inhibitor
EGFR-IN-91 is a selective inhibitor of the epidermal growth factor receptor (EGFR), effective against the EGFR L858R/C797S and EGFR exon 19 deletion/C797S mutants. This compound demonstrates significant anticancer activity by inducing tumor regression in patient-derived xenograft models, making it a valuable tool for research in localized and metastatic non-small cell lung cancer (NSCLC) driven by EGFR mutations. Additionally, EGFR-IN-91's ability to penetrate the blood-brain barrier suggests potential applications in treating brain metastases associated with NSCLC. -
EGFR Inhibitor
RG 14921 is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. This compound functions as a noncompetitive inhibitor, effectively blocking EGFR signaling pathways and CAMP-dependent kinase activity. RG 14921 is utilized in research applications focused on cancer biology, particularly in studies investigating the role of EGFR in tumorigenesis and therapeutic resistance. -
EGFR Tyrosine Kinase Inhibitor
Simotinib hydrochloride is a selective EGFR tyrosine kinase inhibitor, demonstrating an IC50 of 19.9 nM. This compound exhibits potent antineoplastic activity, making it a valuable tool for cancer research and therapeutic development targeting EGFR-associated malignancies. Its oral bioavailability enhances its potential for in vivo studies. -
EGFR Inhibitor
EGFR-IN-160 is a selective EGFR inhibitor, exhibiting IC50 values of 1.62 μM, 0.49 μM, and 0.98 μM against EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S variants, respectively. This compound effectively induces G2/M and S phase cell cycle arrest and apoptosis in NCI-H522 lung cancer cells, showcasing its potential as an anticancer agent. Additionally, EGFR-IN-160 demonstrates antioxidant properties, as evidenced by its IC50 values of 12.11 µM against DPPH and 8.89 µM against H2O2, further supporting its relevance in cancer research and therapeutic development. -
Anti-EGFR Antibody
MM-151 is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR). By binding to multiple regions of the EGFR extracellular domain, MM-151 effectively inhibits EGFR signaling and cell proliferation while reducing mutations in circulating cell-free tumor DNA associated with EGFR resistance. This reagent is valuable for research into drug-resistant cancers, including colorectal cancer, non-small cell lung cancer, and triple-negative breast cancer. -
EGFR Inhibitor
PD 173955 analog 1 is a selective inhibitor of the epidermal growth factor receptor (EGFR) kinase. This compound demonstrates significant antitumor activity and has been characterized for its toxicological effects. In silico studies have reported an IC50 value of 0.19 μM, indicating its efficacy in modulating EGFR-related signaling pathways, making it a valuable tool for cancer research and therapeutic investigations. -
EGFR Inhibitor
EGFR-IN-166 is a selective inhibitor of the epidermal growth factor receptor (EGFR). This compound demonstrates potent anticancer activity, exhibiting IC50 values of 69.63 μM and 22.84 μM against MCF-7 and MDA-MB-231 breast cancer cell lines, respectively. In addition to its cytotoxic effects, EGFR-IN-166 significantly reduces cell migration and decreases EGFR expression. This reagent is valuable for research in breast cancer therapies and mechanisms of EGFR signaling. -
EGFR Inhibitor
EGFR-IN-202 is an inhibitor of the epidermal growth factor receptor (EGFR) that specifically targets exon 20 insertion mutations. This compound demonstrates significant biological activity by inhibiting aberrant signaling pathways associated with non-small cell lung cancer (NSCLC). EGFR-IN-202 is suitable for research applications focused on understanding the mechanisms of resistance in NSCLC and evaluating potential therapeutic strategies. -
EGFR Inhibitor
EGFR-IN-16 is a selective inhibitor targeting the epidermal growth factor receptor (EGFR) with a pIC50 of 4.85. Additionally, it exhibits inhibition of HER-2 with a pIC50 of 4.74, emphasizing its dual-target potential. This compound is useful for research focused on cancer biology, particularly in studies involving EGFR and HER-2 signaling pathways. EGFR-IN-16 can aid in the development of therapeutic strategies for EGFR-driven malignancies. -
PROTAC EGFR Degrader
PROTAC EGFR Degrader 3 is a potent PROTAC designed to selectively target and degrade mutant EGFR proteins. It demonstrates remarkable cellular activity in H1975 and HCC827 cell lines, effectively facilitating the lysosomal degradation of EGFR mutants. This compound is particularly useful for research applications focused on targeted protein degradation and the study of EGFR-related signaling pathways in cancer. -
Mutant EGFR/HER2 Inhibitor
EGFR/HER2-IN-13 is a potent inhibitor targeting mutant forms of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) that exhibit resistance to conventional therapies. This compound demonstrates significant biological activity against these mutants, making it a valuable tool for cancer research, particularly in studies aimed at understanding resistance mechanisms and developing novel therapeutic strategies. -
EGFR Inhibitor
EGFR/ErbB-2 inhibitor-1 is a selective inhibitor targeting the epidermal growth factor receptor (EGFR) and ErbB-2/HER2. This compound demonstrates potent inhibition of EGFR-related signaling pathways and is used in research focused on cancer therapies, particularly breast cancer and other tumors overexpressing HER2. Its ability to interfere with receptor dimerization and downstream signaling makes it valuable for studies on targeted cancer treatments and resistance mechanisms. -
EGFR Inhibitor
AST5902 mesylate is a potent EGFR inhibitor that demonstrates significant antineoplastic activity. As a principal metabolite of Alflutinib, it plays a crucial role in the treatment of non-small cell lung cancer, effectively targeting activating EGFR mutations. Additionally, AST5902 mesylate shows promise in overcoming resistance associated with the EGFR T790M mutation, making it a valuable tool for cancer research and therapeutic development. -
EGFR Inhibitor
EGFR-IN-43 is a potent inhibitor of the epidermal growth factor receptor (EGFR) with sub-nanomolar activity. This compound uniquely fuses tamoxifen or endoxifen with the EGFR inhibitor gefitinib through a covalent bond, allowing it to exhibit both estrogen receptor antagonist properties and effective EGFR inhibition. EGFR-IN-43 demonstrates enhanced anti-cancer effects, making it a valuable tool for studies on targeted therapies in cancer research. -
EGFR Inhibitor
EGFR-IN-123 is a potent inhibitor of the epidermal growth factor receptor (EGFR). This compound demonstrates significant efficacy against cancer cell lines, including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM, respectively. EGFR-IN-123 is suitable for research applications focused on targeted cancer therapies and understanding EGFR signaling pathways.
